Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $286.43M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 1.31M
Average 1.78M
Returns on capital
Fulcrum Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.5%
avg -234.4%
ROIC
-23.8%
avg -201.9%
ROA
-20.4%
avg -93.5%
Analysis
ROA is currently the strongest return metric at -20.4% versus its period average of -93.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alexander C. Sapir | Chief Executive Officer, President & Director | USD 1.2M | 59 | — | — |
Alan A. Musso | CFO, Treasurer & Principal Accounting Officer | USD 802.22K | 64 | 170.00K | 0.31% |
Curtis G. Oltmans | Chief Legal Officer, Head of External Affairs & Corporate Secretary | USD 689.5K | 63 | — | — |
Bobby Riehle | Head of Program Strategy & Vice President | — | — | — | — |
Danny Reinberg | Founder | — | — | — | — |
Michael R. Green | Founder | — | — | — | — |
Iain Fraser DPHIL | Senior Vice President of Early Development | — | — | — | — |
Rudolf Jaenisch | Founder | — | — | — | — |
Tsun-Huei Lee | Founder | — | 62 | — | — |
Bradley E. Bernstein | Founder | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$1.49M
Sells
9
$59.15M
Net Transaction Value
−$57.67M
Net selling
Most Active
TANG KEVIN
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 17, 26Jul 17, 2026 | TANG KEVIN Indirect | Buy | $179.3K$179,326.40 |
| Jul 16, 26Jul 16, 2026 | TANG KEVIN Indirect | Buy | $415.3K$415,348.76 |
| Jul 15, 26Jul 15, 2026 | TANG KEVIN Indirect | Buy | $382.3K$382,262.12 |
| Jul 14, 26Jul 14, 2026 | TANG KEVIN Indirect | Buy | $271.9K$271,908.16 |
| Jul 14, 26Jul 14, 2026 | TANG KEVIN Indirect | Buy | $191K$190,997.56 |
| Jul 13, 26Jul 13, 2026 | TANG KEVIN Indirect | Buy | $45.9K$45,899.64 |
| Jun 26, 26Jun 26, 2026 | Ezekowitz Alan Direct | Sell | $65.6K$65,613.60 |
| Feb 2, 26Feb 2, 2026 | Gould Robert J Direct | Sell | $160.9K$160,857.00 |
| Jan 2, 26Jan 2, 2026 | Gould Robert J Direct | Sell | $163.1K$163,089.00 |
| Jan 2, 26Jan 2, 2026 | Gould Robert J Direct | Sell | $178.1K$178,089.00 |
1–10 of 15
Summary
Insiders reported 6 buys worth $1.49M and 9 sells worth $59.15M over the last 12 months. That adds up to net selling of $57.67M. TANG KEVIN was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Fulcrum Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FULC's management, answered from reported figures.
Who manages FULC?
Fulcrum Therapeutics, Inc. (FULC) lists 10 active executives. The top listed executive is Bobby Riehle, Head of Program Strategy & Vice President.
Are FULC insiders buying or selling?
Recent insider activity shows net buying of $46.24M.
Continue the stock analysis
Jump to another research area for this company.